Bank of America’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $805M | Buy |
1,291,053
+101,469
| +9% | +$69.1M | 0.05% | 304 |
|
|
2026
Q1 | $919M | Buy |
1,189,584
+32,158
| +3% | +$24.6M | 0.07% | 263 |
|
|
2025
Q4 | $893M | Buy |
1,157,426
+3,493
| +0.3% | +$2.37M | 0.07% | 267 |
|
|
2025
Q3 | $649M | Sell |
1,153,933
-66,426
| -5% | -$37.6M | 0.04% | 368 |
|
|
2025
Q2 | $641M | Buy |
1,220,359
+176,122
| +17% | +$98.3M | 0.05% | 357 |
|
|
2025
Q1 | $662M | Buy |
1,044,237
+104,039
| +11% | +$71.6M | 0.05% | 336 |
|
|
2024
Q4 | $670M | Sell |
940,198
-53,039
| -5% | -$44.5M | 0.06% | 314 |
|
|
2024
Q3 | $1.04B | Buy |
993,237
+25,133
| +3% | +$28M | 0.08% | 237 |
|
|
2024
Q2 | $1.02B | Buy |
968,104
+84,036
| +10% | +$81.5M | 0.09% | 230 |
|
|
2024
Q1 | $851M | Buy |
884,068
+5,655
| +0.6% | +$5.38M | 0.08% | 261 |
|
|
2023
Q4 | $772M | Buy |
878,413
+41,554
| +5% | +$34.2M | 0.08% | 256 |
|
|
2023
Q3 | $689M | Sell |
836,859
-1,686
| -0.2% | -$1.33M | 0.08% | 256 |
|
|
2023
Q2 | $603M | Sell |
838,545
-108,865
| -11% | -$83.9M | 0.06% | 280 |
|
|
2023
Q1 | $778M | Buy |
947,410
+53,728
| +6% | +$40.5M | 0.08% | 244 |
|
|
2022
Q4 | $645M | Sell |
893,682
-154,802
| -15% | -$114M | 0.07% | 267 |
|
|
2022
Q3 | $722M | Sell |
1,048,484
-13,820
| -1% | -$8.7M | 0.09% | 233 |
|
|
2022
Q2 | $628M | Sell |
1,062,304
-86,940
| -8% | -$56.5M | 0.07% | 259 |
|
|
2022
Q1 | $803M | Sell |
1,149,244
-12,070
| -1% | -$7.64M | 0.08% | 242 |
|
|
2021
Q4 | $733M | Buy |
1,161,314
+5,040
| +0.4% | +$3.1M | 0.07% | 267 |
|
|
2021
Q3 | $700M | Buy |
1,156,274
+40,430
| +4% | +$25.1M | 0.07% | 262 |
|
|
2021
Q2 | $623M | Sell |
1,115,844
-63,967
| -5% | -$32.4M | 0.06% | 289 |
|
|
2021
Q1 | $558M | Buy |
1,179,811
+67,688
| +6% | +$33M | 0.06% | 287 |
|
|
2020
Q4 | $537M | Sell |
1,112,123
-96,777
| -8% | -$52.2M | 0.07% | 259 |
|
|
2020
Q3 | $677M | Sell |
1,208,900
-37,221
| -3% | -$22.6M | 0.09% | 207 |
|
|
2020
Q2 | $777M | Buy |
1,246,121
+59,175
| +5% | +$33.6M | 0.12% | 171 |
|
|
2020
Q1 | $580M | Buy |
1,186,946
+57,954
| +5% | +$23.9M | 0.1% | 198 |
|
|
2019
Q4 | $424M | Buy |
1,128,992
+18,385
| +2% | +$6.19M | 0.06% | 301 |
|
|
2019
Q3 | $308M | Sell |
1,110,607
-26,961
| -2% | -$7.98M | 0.05% | 370 |
|
|
2019
Q2 | $356M | Sell |
1,137,568
-108,109
| -9% | -$36M | 0.05% | 332 |
|
|
2019
Q1 | $511M | Sell |
1,245,677
-2,027
| -0.2% | -$835K | 0.08% | 249 |
|
|
2018
Q4 | $466M | Buy |
1,247,704
+10,749
| +0.9% | +$3.93M | 0.08% | 247 |
|
|
2018
Q3 | $500M | Sell |
1,236,955
-63,776
| -5% | -$24.3M | 0.08% | 262 |
|
|
2018
Q2 | $449M | Buy |
1,300,731
+120,220
| +10% | +$37.6M | 0.07% | 263 |
|
|
2018
Q1 | $407M | Buy |
1,180,511
+232,256
| +24% | +$80.8M | 0.07% | 275 |
|
|
2017
Q4 | $357M | Sell |
948,255
-663,007
| -41% | -$269M | 0.06% | 310 |
|
|
2017
Q3 | $720M | Buy |
1,611,262
+488,243
| +43% | +$232M | 0.11% | 193 |
|
|
2017
Q2 | $552M | Buy |
1,123,019
+24,345
| +2% | +$10.7M | 0.11% | 198 |
|
|
2017
Q1 | $426M | Buy |
1,098,674
+103,265
| +10% | +$38.3M | 0.08% | 243 |
|
|
2016
Q4 | $365M | Buy |
995,409
+133,273
| +15% | +$50.7M | 0.08% | 260 |
|
|
2016
Q3 | $347M | Buy |
862,136
+221,422
| +35% | +$88.8M | 0.08% | 264 |
|
|
2016
Q2 | $224M | Buy |
640,714
+131,490
| +26% | +$50.6M | 0.05% | 351 |
|
|
2016
Q1 | $184M | Sell |
509,224
-141,607
| -22% | -$58.4M | 0.04% | 401 |
|
|
2015
Q4 | $353M | Buy |
650,831
+93,427
| +17% | +$50.6M | 0.08% | 261 |
|
|
2015
Q3 | $259M | Buy |
557,404
+121,782
| +28% | +$65.4M | 0.06% | 316 |
|
|
2015
Q2 | $222M | Buy |
435,622
+3,484
| +0.8% | +$1.7M | 0.07% | 298 |
|
|
2015
Q1 | $195M | Sell |
432,138
-26,165
| -6% | -$11.1M | 0.07% | 306 |
|
|
2014
Q4 | $188M | Sell |
458,303
-92,444
| -17% | -$36.4M | 0.07% | 333 |
|
|
2014
Q3 | $199M | Sell |
550,747
-108,724
| -16% | -$36.4M | 0.06% | 330 |
|
|
2014
Q2 | $186M | Sell |
659,471
-98,471
| -13% | -$29.2M | 0.06% | 342 |
|
|
2014
Q1 | $228M | Buy |
757,942
+21,092
| +3% | +$6.5M | 0.08% | 247 |
|
|
2013
Q4 | $203M | Buy |
736,850
+92,074
| +14% | +$26.5M | 0.07% | 275 |
|
|
2013
Q3 | $202M | Buy |
644,776
+38,761
| +6% | +$10.2M | 0.08% | 248 |
|
|
2013
Q2 | $136M | Buy |
+606,015
| New | +$141M | 0.06% | 339 |
|
Other funds holding REGN
Bank of America's REGN Position: Q2 2026 in Review
Bank of America increased its Regeneron Pharmaceuticals (REGN) stake by 8.5% in Q2 2026, buying an estimated $69.1M and bringing the position to 1,291,053 shares worth $805M. The position accounts for 0.05% of the portfolio, ranked #304.
Bank of America first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.04B in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Bank of America held 1,291,053 shares of Regeneron Pharmaceuticals worth $805M as of Q2 2026.
- Bank of America bought 101,469 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $69.1M.
- Regeneron Pharmaceuticals made up 0.05% of Bank of America's portfolio in Q2 2026, its #304 holding.
- Bank of America first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of America's Regeneron Pharmaceuticals position peaked at $1.04B in Q3 2024.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.